Improving the design of animal toxicity tests
In the long run, it would be highly desirable to replace all animal toxicity tests by in vitro tests, as suggested by a committee of the US National Academy of Sciences in 2007. 2 However, research to make this possible will probably take many years. In the meantime, the animal tests need to be substantially improved. According to the FDA, 3 "The traditional tools used to assess product safety -animal toxicology and outcomes from human studies -have changed little over many decades, and have largely not benefited from recent gains in scientific knowledge. The inability to better assess and predict product safety leads to failures during clinical development and, occasionally, after marketing. …these failures before human testing or early in clinical trials dramatically escalate costs".
Following this, the FDA set up the Critical Path Initiative 4 and the European Union budgeted two billion Euros to support the Innovative Medicines Initiative (IMI). 5 Both of these aim to improve methods of developing new drugs. But there is one simple way in which scientists could substantially improve testing methods and pave the way for the personalised medicine of the future, without using any more animals. They should control and identify the genetic variation in the rats and mice used in their experiments -something which they completely fail to do at present.
In their chapter on Reduction, Russell and Burch note that the accuracy of an experiment "…depends on the size of the sample, the extent to which individuals of the species vary in response to the drug, and the efficiency in design and analysis of our experiment" (their italics). Individual variation includes both genetic and non-genetic components. Toxicologists attempt to control the non-genetic component, but they make no attempt to control the genetic variation. Russell and Burch go on to say that, "Toxicity testing, as usual…, is the scene of some confused thought, which may be delaying the exploitation of statistical methods. We have not infrequently heard the opinion expressed that… in toxicity tests you need a thoroughly heterogeneous mass of animals, and plenty of them. The physician, it is argued, is going to deal with patients with a very wide range of sensitivities to a given toxic action. There is a vague feeling that since this variation is quite uncontrolled, that of the test animals ought to be uncontrolled too. On this subject Hume has written, 'The fallacy consists in supposing that in order to obtain a wide inductive base a heterogeneous stock should be used… The proper procedure is, of course to use several different homogeneous samples, by using a plurality of pure lines (or preferably F1 crossbreds)… for otherwise the experimenter deprives himself of the possibility of making a relatively precise estimate of the error…'". This is supported by reference to R.A. Fisher's book on The Design of Experiments, published in 1942. 6 Toxicologists don't dispute these suggestions. They simply ignore them.
Need for a high signal/noise ratio
Most toxicologists recognise the need to control inter-individual variability. It creates noise and reduces the signal/noise ratio, leading to false-negative results. They usually ensure that the animals are of uniform body weight, that they all have the same diet, that they are free of disease, and that they are maintained in a controlled environment. But they should also be uniform for the biomarkers of toxicity which the toxicologists plan to measure. This can be done by using inbred strains. Some toxicologists realise this. In a recent report, 7 the UK Committee on Toxicity (COT) states that "Attempts are made to minimise within-species and within-strain variability in toxicological studies on animal models, e.g. by using defined or inbred strains where available, to improve the ability of the study to detect and characterise effects and to reduce the statistical variance in the dose response." Unfortunately, although the argument for using inbred strains is good, the sentence is factually incorrect. Toxicologists rarely use inbred strains, and by failing to do so they damage the quality of their experiments.
The high fidelity fallacy
Why are they so opposed to the use of inbred strains? It seems to be a clear case of what Russell and Burch, in their chapter on Replacement, call "the high fidelity fallacy". Fidelity is the extent to which a model resembles the target (thing being modelled) in every respect. A cell culture is a low fidelity model of humans, because it is very unlike a human. A nonhuman primate is a high fidelity model, because it more closely resembles a human. Since humans are outbred, it is often argued that we should use outbred animals in our experiments. For example, an anonymous industrial toxicologist claimed, in 2005, that "The variability of toxicity obtained in less well defined animals is a strength in itself, not a problem, when trying to predict safety margin in the non-isogenic human population."
But the fallacy lies in assuming that models need high fidelity. We actually need models capable of discriminating between compounds which are toxic and non-toxic at a given dose level. It does not matter whether it is a black box, a cell culture, a mouse or a primate. It only matters whether it correctly predicts human (or environmental) toxicity. Forget fidelity. It is discrimination which is important. The question which toxicologists should be asking themselves is how they can design their animal experiments to give maximum discrimination between toxic and non-toxic compounds. The answer is clear. Aim for a high signal/noise ratio. Control the interindividual variability by using inbred strains, and use several of them, because any one strain may be resistant, exactly as explained by Russell and Burch. This can be done without increasing the total number of animals required, by using a factorial experimental design, as pointed out by R.A. Fisher 66 years ago. We do not want our models to be like humans in every respect. A good toxicological model should certainly not model the uncontrolled genetic variation found in humans. Clinical trials need to be large, because humans are so variable. The doseresponse curve estimated by the industrial toxicologist quoted above will be highly inaccurate, because of the variability of the animals, but he will leave it to his clinical trials colleagues to find this out, at great expense.
A minimally improved design
A 28-day toxicity test usually involves four dose levels, both sexes and ten outbred (e.g. Sprague-Dawley [SD]) rats per group, giving a total of 80 animals. In order to make the minimum change to current methods, an experiment involving, say, three rat strains (e.g. strains F344, BN and DA), with three animals of each strain in each group instead of the ten SD rats currently used, might be appropriate. This experiment would now involve four dose levels, both sexes, three strains, and, with three rats per group, a total of 72 rats. What are the implications of this design?
-Would it be practical? Commercial breeders should have no difficulty in supplying 12 rats of each sex (a couple of litters) of each of the three strains, particularly if given sufficient notice.
Once the experiment was set up, it could be run in exactly the same way as current experiments, so any claim that it would be impractical would be hard to justify. To make it even easier, the three strains have different coat colours, and it would be possible to run it as three separate small experiments, each involving just 24 animals, the results of which would then be combined in the statistical analysis. In this case, any strain differences would be confounded with time differences, but this would not be likely to present any problems. The aim is to compare doses, not strains.
-Why choose three strains? The minimum number of animals per dose × sex × treatment group would be two, if genetic variation in response is to be detected (currently, it is one, since each SD rat is genetically different and genetic variation goes undetected). So it would also be possible to do the experiment with two rats of each of five strains. The more strains which are used, the better the sampling of the range of genetic susceptibility, but the less practical the experiment may become.
-How should strains be chosen? One way would be to choose strains which are as unrelated as possible, but are also commercially-available.
Data showing genetic similarity among different rat and mouse strains already exist, [8] [9] as does information on the lifespans, spontaneous pathology and other characteristics of these strains. Further historic data on control animals could be accumulated rapidly, and these would be much more reliable than current data on outbred stocks, which can not even be monitored for authenticity.
-Would it be any more sensitive than existing methods? Unfortunately, toxicologists have never attempted to use such a design. However, a small experiment involving the toxicity of chloramphenicol at six dose levels, compared a single outbred CD-1 group with eight animals per dose versus two animals of each of four inbred strains at the same dose levels. 10 The signal/noise ratio was much higher with the inbred strains, so sensitivity was certainly increased. Whereas the inbred strains showed clear evidence of toxicity to the white blood cells, the CD-1 experiment failed to do so. So, both theory and available evidence show that the multi-strain design would be an improvement over the use of a single outbred stock.
-What other benefits would there be? Multi-strain designs will often show strain differences in susceptibility. Safety should be based on the most sensitive strain, but in some cases it may be worth exploring the nature of these differences, in the hope that the sensitivity genes can be identified. This could help to clarify toxicity mechanisms and provide data which could be used in personalised medicine in the future. There is also a possibility that the number of animals could be reduced, once it was established that sensitivity had been substantially increased.
Improving biomarkers of toxicity
According to the FDA, 3 "Not enough applied scientific work has been done to create new tools to get fundamentally better answers about how the safety and effectiveness of new products can be demonstrated, in faster time frames, with more certainty, and at lower costs." Current biomarkers were appropriate several decades ago, but better ones are urgently needed. This is widely recognised, and the research is under way, both in the Critical Path Initiative and in the IMI. Many promising new techniques are available. They include the "omics" (genomics, expressionomics, proteomics, metabolomics and histomics), as well as behavioural profiling, telemetry and improved imaging methods. These techniques are often expensive and time-consuming, so they will need to be performed in small experiments, in which the treated and control animals are genetically identical. They will also need to be validated in different laboratories. This will be extremely difficult unless the genotypes of the animals are clearly specified. This is impossible when using outbred stocks. An excellent example of how this type of research should be approached, is the development of the local lymph node assay (LLNA) by Ian Kimber. 11 He placed great emphasis on the repeatability of the assay in different laboratories and specified the use of inbred CBA strain mice. If the protocol was then unrepeatable, it was clearly not because the mice were different.
Does the statistical analysis of toxicity studies need to be improved?
According to Russell and Burch, "Every time any particle of statistical method is properly used, fewer animals are employed than would have otherwise been necessary". Yet, anecdotally, it has been suggested that statistics plays very little part in the interpretation of toxicity tests. A typical short-term toxicity test may include data on haematology, clinical biochemistry, organ weights and the results of histological examination and other variables, amounting to more than a hundred observations on each animal -or more than 8000 observations. The resulting data are usually confidential to commercial companies and regulators, so it is not clear what statistical methods are used or how they are interpreted. Where the results of such studies are published, they tend to report fewer outcomes and use fairly conventional statistical methods, with a separate statistical test for each outcome -often with no correction for multiple testing. However, this could lead to false-positive results. On the other hand, a Bonferroni correction 12 would also be inappropriate, as many of the characters are correlated. Multivariate methods, such as principal component analysis (now widely used in the analysis of microarray experiments), may be helpful, but they have the disadvantage of being difficult to understand and therefore to interpret. 13 If several inbred strains are to be used, then this adds extra complexity. While this can still be accommodated with current methods, the whole area probably needs further research. The results of a study need to be summarised in such a way as to make the interpretation as easy as possible. Not all differences between treatment groups are necessarily of toxicological significance.
More-radical changes?
The above proposal of using 3-5 inbred strains with current toxicity assays, is suggested in order to make the minimum possible change. However, if more-radical changes could be considered, an obvious one would be to use the mouse rather than the rat.
The advantages of the mouse include the availability of a wide range of strains and the extensive databases on mouse genetics, the human/ mouse orthology of individual genes, and the relative ease with which mice can be genetically manipulated. Genetically modified strains can, for example, have reporter genes inserted, which "light up" if toxic pathways are activated, before overt toxicity is detectable. 14 Another approach could be to develop more short-term tests, by using just a few biomarkers for a particular type of toxicity, as was done for the LLNA for allergic contact dermatitis. The latter test has a high signal/noise ratio and a high level of repeatability, which permits further reductions in animal numbers. 15 Short-term tests of this type could be used as pre-screening tests, which could be used in some cases to obviate the need for more-general toxicity tests. Once toxic mechanisms are better understood, it will be easier to develop in vitro tests.
Identifying human susceptibility genes
One of the most serious limitations of current methods for toxicity testing is that toxicologists rarely become aware of genetic variation in the responses of their test animals. Such variation is most easily seen as differences between strains. Only gross changes, such as hairlessness, changes in coat colour, or large differences within a stock in response to toxic agents, are detectable in outbred stock without extensive genetic investigations.
Genetic variation in response to toxic agents in humans is difficult to identify, because it depends on exposure to the toxic compound and the resulting adverse effects, by which time, the detection of variation is too late. It is much better to detect such variation in animals, identify the genes involved, and then see whether the same genes have a similar effect in humans in early phase trials. As genetic profiling in animals becomes easier, more genes associated with toxic responses will be found, which can then be used in personalised medicine. Unfortunately, the sciences of pharmacogenetics and toxicogenetics are still poorly supported, largely because toxicologists have been blind to animal genetics. It is noticeable, for example, that thousands of mutant and geneticallymodified mice are currently being developed. These are screened for a wide range of characteristics of value in biomedical research, but very rarely for their responses to toxic chemicals, presumably because toxicologists do not "think genetics".
Conclusions
Toxicity testing is at a crossroads. After years of stagnation, the regulators and pharmaceutical industry seem to have woken up to the fact that current methods are inadequate. But they have not yet realised that animals are being wasted in badly-designed experiments, which take no account of genetic variation in the test species. This, in turn, leads to too many false-negative results. Yet the way forward was outlined clearly by Russell and Burch exactly fifty years ago, and has been repeated many times since then. 10, [16] [17] [18] [19] [20] [21] Toxicologists should stop ignoring the genetic variation in their test animals. This should be controlled and made explicit, by using small numbers of several inbred or F1 hybrid strains of rats or, preferably, mice. The use of inbred strains, combined with new biomarkers such as gene expression profiling, behavioural profiling and improved imaging methods, should provide a quantum leap in the sensitivity of animal tests. This will lead to much better characterisation of the effects of each chemical, better identification of gene loci in animals and humans associated with toxic responses, and, in the long run, a reduction in animal use. 
